Download MendeleyFragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction.
Norton, D., Bonnette, W.G., Callahan, J.F., Carr, M.G., Griffiths-Jones, C.M., Heightman, T.D., Kerns, J.K., Nie, H., Rich, S.J., Richardson, C., Rumsey, W., Sanchez, Y., Verdonk, M.L., Willems, H.M.G., Wixted, W.E., Wolfe 3rd, L., Woolford, A.J., Wu, Z., Davies, T.G.(2021) J Med Chem 64: 15949-15972
- PubMed: 34705450
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01351
- Primary Citation of Related Structures:
7P58, 7P5E, 7P5F, 7P5I, 7P5K, 7P5N, 7P5P - PubMed Abstract:
The NRF2-mediated cytoprotective response is central to cellular homoeostasis, and there is increasing interest in developing small-molecule activators of this pathway as therapeutics for diseases involving chronic oxidative stress. The protein KEAP1, which regulates NRF2, is a key point for pharmacological intervention, and we recently described the use of fragment-based drug discovery to develop a tool compound that directly disrupts the protein-protein interaction between NRF2 and KEAP1. We now present the identification of a second, chemically distinct series of KEAP1 inhibitors, which provided an alternative chemotype for lead optimization. Pharmacophoric information from our original fragment screen was used to identify new hit matter through database searching and to evolve this into a new lead with high target affinity and cell-based activity. We highlight how knowledge obtained from fragment-based approaches can be used to focus additional screening campaigns in order to de-risk projects through the rapid identification of novel chemical series.
Organizational Affiliation:
Astex Pharmaceuticals, 436 Cambridge Science Park, Cambridge CB4 0QA, U.K.
